Prognosis in AML-MRC may be better defined by the associated mutational profile; for example, in the presence of wild-type rather than mutated NPM1 [17], or the presence of mutated ASXL1 or TP53 [18]. This evidence concerns the gene NPM1 and acute myeloid leukemia.